Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Ari J RosenbergNishant AgrawalAditya JulooriJohn CursioZhen GooiElizabeth BlairJeffrey ChinDaniel GinatOlga Pasternak-WiseRifat HasinaAnna StarusFrederick S JonesEvgeny IzumchenkoEllen MacCrackenRachelle WolkNicole CiprianiMark W LingenAlexander T PearsonTanguy Y SeiwertDaniel J HarafEverett E VokesPublished in: JAMA oncology (2024)
ClinicalTrials.gov Identifier: NCT03107182.
Keyphrases
- open label
- locally advanced
- papillary thyroid
- rectal cancer
- phase ii study
- study protocol
- phase ii
- clinical trial
- phase iii
- lymph node
- squamous cell
- high grade
- squamous cell carcinoma
- radiation therapy
- lymph node metastasis
- randomized controlled trial
- childhood cancer
- young adults
- cervical cancer screening
- chemotherapy induced